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MS disease activity in RESTORE
A randomized 24-week natalizumab treatment interruption study
ABSTRACT
Objective: RESTOREwas a randomized, partially placebo-controlled exploratory study evaluating
multiple sclerosis (MS) disease activity during a 24-week interruption of natalizumab.
Methods: Eligible patients were relapse-free through the prior year on natalizumab and had no
gadolinium-enhancing lesions on screening brain MRI. Patients were randomized 1:1:2 to con-
tinue natalizumab, to switch to placebo, or to receive alternative immunomodulatory therapy
(other therapies: IM interferon b-1a [IM IFN-b-1a], glatiramer acetate [GA], or methylprednisolone
[MP]). During the 24-week randomized treatment period, patients underwent clinical and MRI
assessments every 4 weeks.
Results: Patients (n 5 175) were randomized to natalizumab (n 5 45), placebo (n 5 42), or other
therapies (n 5 88: IM IFN-b-1a, n 5 17; GA, n 5 17; MP, n 5 54). Of 167 patients evaluable for
efficacy, 49 (29%) had MRI disease activity recurrence: 0/45 (0%) natalizumab, 19/41 (46%)
placebo, 1/14 (7%) IM IFN-b-1a, 8/15 (53%) GA, and 21/52 (40%) MP. Relapse occurred in 4%
of natalizumab patients and in 15%–29% of patients in the other treatment arms. MRI disease
activity recurred starting at 12 weeks (n5 3 at week 12) while relapses were reported as early as
4–8 weeks (n5 2 in weeks 4–8) after the last natalizumab dose. Overall, 50/167 patients (30%),
all in placebo or other-therapies groups, restarted natalizumab early because of disease activity.
Conclusions: MRI and clinical disease activity recurred in some patients during natalizumab inter-
ruption, despite use of other therapies.
Classification of evidence: This study provides Class II evidence that for patients with MS taking
natalizumab who are relapse-free for 1 year, stopping natalizumab increases the risk of MS relapse
or MRI disease activity as compared with continuing natalizumab. Neurology® 2014;82:1491–1498
GLOSSARY
EDSS 5 Expanded Disability Status Scale; GA 5 glatiramer acetate; Gd1 5 gadolinium-enhancing; IFN-b-1a 5 interferon
b-1a;MP5methylprednisolone;MS5multiple sclerosis; PML5 progressive multifocal leukoencephalopathy;QOL5 quality
of life; SDMT 5 Symbol Digit Modalities Test; VAS 5 Visual Analogue Scale.
Natalizumab (Tysabri, Biogen Idec Inc., Cambridge, MA) has demonstrated efficacy in the
treatment of multiple sclerosis (MS).1,2 In patients who are anti–JC virus antibody–positive,
natalizumab treatment duration increases the risk of progressive multifocal leukoencephalopathy
(PML),3–5 although PML in patients with MS may have a better prognosis than PML in HIV-
infected patients.6
Planned dosage interruption has been proposed, hypothetically, as a way to mitigate PML
risk.7–15 To date, there have been no prospective controlled studies of the effects of natalizumab
treatment interruption. Some studies suggest that withdrawal of natalizumab treatment for $3
months may be associated with return of MS disease activity.7–17 Following natalizumab
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discontinuation, MS disease activity exceeded
prenatalizumab disease activity in some stud-
ies9,15,16,18,19 but not in others.13,14,20,21 The tim-
ing of the return of disease activity and optimal
monitoring and treatment strategies for patients
discontinuing natalizumab are not known.
The objectives of RESTORE, a randomized,
partially placebo-controlled study, were to
explore the course of MS disease activity and
the effects on pharmacokinetic, pharmacody-
namic, and immune parameters in patients
undergoing an interruption of natalizumab
therapy for up to 24 weeks as compared with
those in patients remaining on natalizumab.
It also assessed the effects of alternate therapies
during natalizumab interruption. RESTORE
was an exploratory study and was neither de-
signed nor powered for any specific endpoint
or to detect an effect of natalizumab treatment
interruption on PML occurrence.
We present the clinical and MRI outcomes
during natalizumab treatment interruption
and after restarting natalizumab in RESTORE.
METHODS Study design. In this phase 4, randomized, mul-
ticenter, partially placebo-controlled, parallel-group exploratory
study, patients with MS receiving natalizumab were
randomized into 3 treatment arms in a 1:1:2 ratio:
natalizumab:placebo:alternate immunomodulatory therapy
(other therapies: IM interferon b-1a [IM IFN-b-1a] [Avonex,
Biogen Idec Inc., Cambridge, MA], glatiramer acetate [GA]
[Copaxone, Teva Neuroscience, Kansas City, MO], or
methylprednisolone [MP]). In the other-therapies group,
patients and their neurologist selected the immunomodulatory
therapy on an individual basis; as such, the distribution of
patients receiving IM IFN-b-1a, GA, and MP was not
randomized, and the groups were unbalanced (figure 1).
Planned enrollment was approximately 160 patients
randomized 1:1:2 natalizumab:placebo:other therapies. As an
exploratory study, the sample and randomization allocation
were chosen to evaluate trends in radiologic and clinical disease
recurrence in each group. Patients from 31 sites in North America
and Europe were randomized using a centralized interactive voice
response system at the baseline visit, and randomization was
stratified by country and pretreatment disease activity (high vs
low). High disease activity was defined as $2 relapses within
12 months prior to initiating natalizumab therapy. The study
was performed between March 2010 and November 2011.
Standard protocol approvals, registrations, and patient
consents. Each site’s institutional review board reviewed and
approved the study protocol and amendments, and all partici-
pants provided written informed consent. The study was
Figure 1 Study design
Patients provided signed consent at week 24 and underwent screening. Patients were enrolled at their next monthly visit (day/week 0) if they did not have
subclinical disease activity as evidenced by gadolinium-enhancing lesions on MRI and met all other eligibility criteria. At day/week 0, natalizumab-treated
patients were randomized into 1 of 3 treatment arms in a 1:1:2 ratio: natalizumab (no natalizumab treatment interruption), placebo (natalizumab treatment
interruption), or other therapies (IM interferon b-1a [IFN-b-1a], glatiramer acetate [GA], or methylprednisolone [MP] as determined by the patient or the
investigator; natalizumab treatment interruption). All patients received natalizumab infusion on day 0. IM IFN-b-1a or GA was started on day 0, following
natalizumab infusion, and MP was started at week 12 (other-therapies group). Placebo infusions began (placebo group) or natalizumab infusions continued
(natalizumab group) at week 4. If a patient in any treatment arm developed protocol-defined multiple sclerosis disease recurrence, treatment with high-dose
corticosteroids or restarting natalizumab, at the investigators’ discretion, was permitted. Following the 28-week randomized treatment period, placebo and
other therapies were discontinued and natalizumab was restarted in the placebo and other-therapies groups and continued through week 52 (study end) in
the follow-up period. Clinical, MRI, and laboratory evaluations were performed every 4 weeks during the randomized treatment period starting at week 0, at
the time of suspected relapse, and at the week 52 follow-up visit. Expanded Disability Status Scale was assessed at day 0, at week 28, at the time of
suspected relapse, and at the week 52 follow-up visit.
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performed in accordance with the Declaration of Helsinki and
International Conference on Harmonisation Guideline on Good
Clinical Practice and is registered with ClinicalTrials.gov, number
NCT01071083.
Primary research question. This analysis of patients with MS
who were relapse-free for 1 year on natalizumab therapy was
conducted to compare clinical and MRI outcomes during
natalizumab treatment interruption with those in patients
remaining on natalizumab. While the effects of alternative
therapies during natalizumab interruption were also assessed,
RESTORE was not designed to compare the efficacy of the
different alternative therapies.
Classification of evidence. This study provides Class II evi-
dence that for patients with MS taking natalizumab who are
relapse-free for 1 year, stopping natalizumab increases the risk of
MS relapse or MRI disease activity as compared with continuing
natalizumab. Because of differences in baseline characteristics and
the open-label design, the comparisons with the alternative
immunotherapies group provide Class IV evidence.
Patients. RESTORE enrolled patients between 18 and 60 years
of age with relapsing forms of MS who had been treated with na-
talizumab for at least 12 months prior to randomization and who
had no relapses during those 12 months.
Exclusion criteria included the presence of gadolinium-
enhancing (Gd1) lesions on screening MRI; presence of antina-
talizumab antibodies at screening; history of significant infectious
illness or significant disease other than MS; and inability to
undergo monthly MRI scans for 6 months. Patients were also
excluded if they received immunosuppressive treatment within
24 months prior to randomization; treatment with IV immuno-
globulin, plasmapheresis, or cytapheresis within 12 months prior
to randomization; or treatment with systemic corticosteroids
within 3 months prior to randomization.
Interventions. At the baseline visit (day 0), all patients received
a standard 300-mg natalizumab infusion. Starting at week 4,
patients randomized to natalizumab or placebo received
infusions every 4 weeks through week 24 in a double-blind
fashion. Patients randomized to other therapies who chose IM
IFN-b-1a or GA received their first injections on day 0.
Patients randomized to other therapies who chose MP received
infusions every 4 weeks starting at week 12. All 3 other therapies
were administered open-label. Clinical, MRI, and laboratory
evaluations were performed every 4 weeks during the
randomized treatment period starting at week 0, at the time of
suspected relapse, and at the final visit.
At week 28, patients resumed open-label infusions of natalizu-
mab and stopped placebo or other therapy. Participants were fol-
lowed for an additional 24 weeks, concluding the study at week 52.
Treatment for MS disease recurrence. If a patient experi-
enced protocol-defined evidence of MS disease recurrence
during the randomized treatment period, the investigator had the
option of administering high-dose corticosteroid treatment as per
local standard of care or restarting open-label natalizumab
infusions. Because natalizumab discontinuation has been linked
to severe clinical relapses in some studies,15,18,19 disease recurrence
criteria incorporated subclinical measures of radiographic disease
activity as detected by every-4-week brain MRI scans. This
method allowed physicians to use radiographic criteria to initiate
treatment with corticosteroids or restart natalizumab.
Disease recurrence criteria were (1) 1 Gd1 lesion of .0.8
cm3 in volume, (2) 2 or more Gd1 lesions of any size, as reported
by the Central MRI Reading Center (NeuroRx Research,
Montreal, Canada), or (3) a relapse defined as new or recurrent
neurologic symptoms not associated with fever or infection, last-
ing at least 24 hours and associated with any of the following: an
increase of $1 grade in $2 functional scales of the Expanded
Disability Status Scale (EDSS); an increase of $2 grades in one
functional scale of the EDSS; an increase of $1.0 in the overall
EDSS score if the previous overall EDSS score was 0.0–5.5; or an
increase of $0.5 if the previous overall EDSS score was .5.5.
Patients who restarted natalizumab during the randomized
treatment period entered the follow-up period immediately and
were followed on open-label natalizumab for 24 weeks. The
end of the follow-up period for these patients was considered
“week 52,” even though their total study time may have been
less than 52 weeks.
Assessments. The objective of this study was to assess radio-
graphic and clinical disease activity in patients with MS undergo-
ing up to a 24-week interruption of natalizumab therapy. The
time course to return of radiologic or clinical evidence of MS
activity was assessed by Gd1 lesions on cranial MRI and
clinical relapse.
Evaluations of quality of life (QOL) using a Visual Analogue
Scale (VAS), fatigue using the Modified Fatigue Impact Scale, and
cognition using the Symbol Digit Modalities Test (SDMT) were
performed at the same time points as clinical, MRI, and laboratory
evaluations (every 4 weeks during the randomized treatment period
starting at week 0, at the time of suspected relapse, and at the final
visit). EDSS was assessed at day 0, at week 28, at the time of sus-
pected relapse, and at the final visit. EDSS and SDMT evaluations
were performed by clinical staff blinded to treatment assignment.
The Central MRI Reading Center that performed MRI assessments
was blinded to treatment allocation. Investigators assessed patient
safety by physical examination (including vital signs), concomitant
therapy and procedure recording, laboratory tests, and adverse event
and serious adverse event recording.
Statistical analysis. All efficacy analyses were performed on an
evaluable population that completed the study through at least
week 4 and did not incur any of the following major protocol de-
viations: testing positive for anti-IFN-b-1a antibodies and choos-
ing IFN-b-1a as an alternative immunomodulatory therapy, not
receiving the day 0 (baseline) natalizumab dose, and being previ-
ously randomized into the study.
Baseline comparisons were performed using a 1-way analysis
of variance for continuous variables and Fisher exact test for pro-
portions. Other proportions are presented with exact binomial
confidence intervals and were compared using Fisher exact test.
Kaplan-Meier analyses were performed and p values from log-
rank tests are provided.
RESULTS Patient demographics and disease characteristics.
A total of 175 patients were enrolled. Forty-five
patients (26%) were randomized to natalizumab,
42 patients (24%) were randomized to placebo,
and 88 patients (50%) were randomized to other
therapies. In the other-therapies group, 17 of 88
patients (19%) received IM IFN-b-1a, 17 of 88
patients (19%) received GA, and 54 of 88 patients
(61%) received MP. Forty-three of 45 natalizumab
patients (96%), 35 of 42 placebo patients (83%),
and 73 of 88 other-therapies patients (83%)
completed the study. Reasons for withdrawing from
the study included withdrawal of consent, refusal to
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return for the protocol-defined monthly visits, and
inclusion/exclusion criteria violations.
Except for baseline EDSS score, baseline demo-
graphics and disease characteristics were similar across
the groups (table 1). Seventy-three percent of
RESTORE patients had prior IFN-b-1a use, 37%
had prior GA use, and 33% had prior IFN-b-1b use.
MRI disease activity. During the randomized treat-
ment period, 49 of 122 patients (40%) randomized
to placebo or other therapies had MRI activity meet-
ing disease recurrence criteria, while none of the pa-
tients randomized to natalizumab had MRI activity
meeting the criteria (p , 0.001). Thirty-four
percent (23/68) of patients with high disease
activity prior to natalizumab treatment had MRI
activity meeting criteria during the randomized
treatment period; the proportion was 26% (26/99)
for those with low disease activity prior to
natalizumab treatment (p 5 0.305; table 2). No
MRI activity meeting defined disease recurrence
criteria was detected prior to week 12. A total of 49
patients developed MRI findings that met defined
criteria for disease recurrence; 3 patients (6%) at
week 12, 37 patients (76%) at week 16 or 20, and
9 patients (18%) after week 20 (figure 2A).
Relapse. Twenty-three of 122 patients (19%) off nata-
lizumab and 2 of 45 patients (4%) on natalizumab
experienced relapses during the randomized treatment
period (p5 0.026). Relapses occurred in 21% (14/68)
of patients with high disease activity and in 11% (11/
99) of patients with low disease activity prior to start-
ing natalizumab (p 5 0.122; table 2). Of 25 relapses
occurring during the randomized treatment period, 2
(8%) occurred between weeks 4 and 8, 9 (44%)
occurred between weeks 8 and 16, and 14 (56%)
occurred between weeks 16 and 28 (figure 2B). Two
patients with high disease activity (in GA and MP
groups) experienced a relapse in both the randomized
treatment period and in the follow-up period.
Natalizumab restart. During the randomized treatment
period, 50 patients restarted open-label natalizumab,
including 12 patients who experienced a clinical
relapse without MRI activity and 7 patients who had
both a clinical relapse and MRI activity. Thirty-one
of 40 patients (78%) who met MRI criteria without
experiencing a clinical relapse restarted natalizumab;
an additional 2 patients were treated with steroids.
Time to restarting natalizumab is shown in figure 2C.
QOL, fatigue, and cognition. Measures of QOL,
fatigue, and cognition were exploratory measures
and analyzed separately for patients who continued
on their randomized treatment through week 28
and for those who restarted natalizumab earlier due
to disease recurrence. Patients experiencing disease
activity showed a mean decrease from baseline in
VAS score at the time of relapse (results are provided
in table e-1 and figure e-1 on theNeurology®Web site
at Neurology.org).
Follow-up. At the week 52 follow-up visit, after 24
weeks of open-label natalizumab, one patient in
the placebo group had 1 Gd1 lesion on MRI; no
other patients in any group had MRI activity. Five
percent of patients (8/155) had relapses during the
Table 1 Baseline demographics, disease characteristics, and prior therapies
Characteristic Natalizumab (n 5 45) Placebo (n 5 42) IM IFN-b-1a (n 5 17) GA (n 5 17) MP (n 5 54)
Age, y, mean 6 SD 41.2 6 9.7 40.0 6 10.4 45.1 6 9.9 44.1 6 7.9 40.1 6 10.0
Female patients, % 82 74 82 82 72
Race, white, % 82 93 100 100 93
EDSS score at baseline, mean 6 SDa 3.0 6 1.8 3.3 6 1.8 2.8 6 1.6 4.5 6 2.1 3.0 6 1.4
High disease activity prior to natalizumab, %b 42 45 24 47 35
Disease duration, y, mean 6 SD 10.1 6 5.9 10.1 6 7.2 10.4 6 4.5 7.8 6 4.9 8.9 6 6.7
No. of prior natalizumab infusions, median (range) 29 (12–49) 31 (13–51) 25 (12–46) 25 (13–45) 28 (13–50)
Prior therapies, n (%)
IFN-b-1a 35 (78) 30 (71) 12 (71) 11 (65) 39 (72)
GA 18 (40) 18 (43) 6 (35) 8 (47) 15 (28)
IFN-b-1b 13 (29) 11 (26) 6 (35) 5 (29) 22 (41)
Corticosteroids 6 (13) 7 (17) 2 (12) 2 (12) 2 (4)
Mitoxantrone 6 (13) 4 (10) 0 1 (6) 3 (6)
Methotrexate 1 (2) 4 (10) 1 (6) 0 3 (6)
Abbreviations: EDSS 5 Expanded Disability Status Scale; GA 5 glatiramer acetate; IFN-b-1a 5 interferon b-1a; MP 5 methylprednisolone.
a All baseline characteristics were well-balanced among the study groups (nominal p . 0.05) with the exception of EDSS score at baseline (p 5 0.016).
bHigh disease activity was defined as $2 relapses occurring within the 12 months prior to initiating natalizumab therapy.
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follow-up period; 5 of the 8 patients were not
receiving natalizumab during the randomized
treatment period, and 3 patients had a relapse
within 4 weeks of reinitiation of open-label
natalizumab treatment. Nineteen of 175 patients
(11%) did not receive natalizumab during the
follow-up period, and one patient was excluded
from the analysis.
Safety. During the randomized treatment and
follow-up periods, the majority of patients in all
groups had at least one adverse event: randomized
treatment period: natalizumab, 84% (n 5 38);
placebo, 83% (n 5 35); IM IFN-b-1a, 88%
(n 5 15); GA, 88% (n 5 15); MP, 78% (n 5 42);
follow-up period: natalizumab, 58% (n 5 25);
placebo, 51% (n 5 19); IM IFN-b-1a, 69%
(n 5 9); GA, 73% (n 5 11); MP, 50% (n 5 24).
Adverse events were primarily mild or moderate in
severity, and the most frequently reported adverse
events were generally consistent with MS and
disease-modifying therapy product labels, but also
included upper respiratory tract infection,
nasopharyngitis, and influenza-type illness (table e-2).
Four patients withdrew from the study during the
randomized treatment period due to severe fatigue
(placebo), moderate muscular weakness (placebo),
mild hypoesthesia (IM IFN-b-1a), and a serious
adverse event of brain abscess (MP). There were no
deaths during the study.
DISCUSSION Natalizumab is often used to treat pa-
tients whose disease has been inadequately controlled
with other therapies, and natalizumab-treated
patients are at significant risk of disease recurrence
following treatment cessation. RESTORE is the
largest randomized prospective study to date
analyzing MS disease recurrence during natalizumab
treatment interruption in a subpopulation of
patients who had been stable on natalizumab for
over a year with no Gd1 lesions at baseline.
Disease recurred in a large proportion of
RESTORE patients who discontinued natalizumab
treatment, and radiologic disease recurrence was
more frequent in patients with high disease activity
(based on relapses) prior to natalizumab therapy than
in patients with low disease activity prior to starting
natalizumab.22 The safety evaluations were generally
consistent with the labeled risk profile for each of
the respective marketed products, notably for
natalizumab.
Similar to smaller observational studies and retros-
pective analyses,8,10–12,15,18 RESTORE demonstrated
that natalizumab treatment interruption resulted in
occurrence of MRI disease activity as early as 12
weeks, and of clinical disease activity as early as 4–8
weeks, after the last natalizumab dose. The earlier
recurrence of clinical disease vs radiologic disease
may also reflect the more subjective nature of clinical
relapse reporting, although our study design required
objective EDSS changing for defining a clinical
Table 2 Patients with disease recurrence during the randomized treatment period
All patients, n (%) (95% CI) High disease activity, n (%) (95% CI)a Low disease activity, n (%) (95% CI)
Patients with MRI disease recurrenceb
Total 49/167 (29) (22.6–36.9) 23/68 (34) (22.8–46.3) 26/99 (26) (17.9–36.1)
Natalizumab 0/45 (0) (0–7.9) 0/19 (0) (0–17.6) 0/26 (0) (0–13.2)
Placebo 19/41 (46) (30.7–62.8) 11/19 (58) (33.5–79.7) 8/22 (36) (17.2–59.3)
Other therapies
IM IFN-b-1a 1/14 (7) (0.2–33.9) 0/4 (0) (0–60.2) 1/10 (10) (0.3–45.5)
GA 8/15 (53) (26.6–78.7) 5/7 (71) (29.0–96.3) 3/8 (38) (8.5–75.5)
MP 21/52 (40) (27.0–54.9) 7/19 (37) (16.3–61.6) 14/33 (42) (25.5–60.8)
Patients with relapse
Total 25/167 (15) (9.9–21.3) 14/68 (21) (11.7–32.1) 11/99 (11) (5.7–19.0)
Natalizumab 2/45 (4) (0.5–15.1) 2/19 (11) (1.2–33.1) 0/26 (0) (0–13.2)
Placebo 7/41 (17) (7.2–32.1) 2/19 (11) (1.2–33.1) 5/22 (23) (7.8–45.4)
Other therapies
IM IFN-b-1a 4/14 (29) (8.4–58.1) 2/4 (50) (6.8–93.2) 2/10 (20) (2.5–55.6)
GA 4/15 (27) (7.8–55.1) 3/7 (43) (9.9–81.6) 1/8 (13) (0.3–52.7)
MP 8/52 (15) (6.9–28.1) 5/19 (26) (9.1–51.2) 3/33 (9) (1.9–24.3)
Abbreviations: CI 5 confidence interval; GA 5 glatiramer acetate; Gd1 5 gadolinium-enhancing; IFN-b-1a 5 interferon b-1a; MP 5 methylprednisolone.
aHigh disease activity was defined as $2 relapses occurring within the 12 months prior to initiating natalizumab therapy.
bMRI criteria were defined as 1 new Gd1 lesion of .0.8 cm3 or 2 or more Gd1 lesions of any size as determined by the central reader.
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relapse. While most studies report that disease recurs
an average of $3 months after the last natalizumab
dose,7,9–15,17,18,20 relapses occurring during the first
1–3 months have also been observed.7,11,12,14,15,20
The emergence of MRI disease activity is consistent
with RESTORE pharmacodynamic data, which
showed that pharmacodynamic markers were consis-
tent with levels in non–natalizumab-treated patients
at 16 weeks after the last dose.22
In RESTORE, GA starting after the last dose of
natalizumab and monthly MP starting 12 weeks after
the last natalizumab dose did not appear to be effec-
tive in disease suppression, as compared with contin-
ued natalizumab treatment. Starting MP at 12 weeks
may have been too late to prevent disease activity,
although most patients randomized to MP did not
have disease recurrence until after 12 weeks. There
appeared to be less recurrence of MRI disease activity
with IM IFN-b-1a than with other open-label treat-
ments, although the IM IFN-b-1a group had a lower
proportion of patients with high disease activity
prenatalizumab than the other groups. However,
patients were not randomly assigned to specific
treatments within the other-therapy group, and
RESTORE was neither designed nor adequately pow-
ered to compare the efficacy of the different alterna-
tive immunomodulatory therapies. Therefore, larger
controlled trials would be needed to confirm this
observation.
Findings on alternative immunomodulatory drug
use during natalizumab treatment interruption have
been mixed. A large retrospective study of more than
1,800 patients showed that during natalizumab treat-
ment interruption, MS disease activity returned to
baseline levels within 4–7 months, regardless of
whether patients received immunomodulatory thera-
pies.20 Data from 2 small studies suggested that im-
munomodulating therapies (IM IFN-b-1a or GA)
reduced MS disease activity recurrence during natali-
zumab treatment interruption.14,21 In other studies,
use of GA or MP, or fingolimod during natalizumab
treatment interruption was associated with recurrence
of disease activity to higher levels than that seen dur-
ing natalizumab use.8,9,13,16,23 It is unknown whether
other disease-modifying therapies might maintain the
low rate of clinical and radiologic disease activity
in natalizumab-treated patients who discontinue
natalizumab.
Some studies have suggested that MS disease
activity returns to a higher than baseline level during
natalizumab treatment interruption,9,15,16,18,19
although larger studies have not shown evidence of
overshoot.13,20,21 The nature of MRI disease recur-
rence in RESTORE will be characterized in more
detail in a separate report.
This study used serial monthly MRI scans follow-
ing natalizumab discontinuation and specific disease
activity criteria for resuming natalizumab treatment.
The majority of patients who experienced defined
MRI disease activity restarted natalizumab during
Figure 2 Time to MRI disease recurrence, relapse, and restarting natalizumab
prior to week 28 due to disease recurrence
Time to (A) MRI disease recurrence, (B) relapse, and (C) restarting natalizumab prior to week 28
due to disease recurrence. GA 5 glatiramer acetate; IFN-b-1a 5 interferon b-1a; MP 5 meth-
ylprednisolone. p Values from log-rank tests are as follows: (A) p, 0.0001, (B) p5 0.0843, (C)
p , 0.0001.
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the randomized treatment period despite the absence
of clinical symptoms, suggesting that physicians made
clinical decisions based on MRI findings. It is plausi-
ble that use of MRI criteria for restarting natalizumab
treatment following discontinuation reduced the
occurrence of severe clinical relapses that have been
reported in other studies. Results from RESTORE
and other studies suggest that, in patients who discon-
tinue natalizumab, brain MRI surveillance beginning
12–16 weeks after the last natalizumab infusion may
be useful for identifying patients with a return of
disease activity.24
The results suggest planned dosage interruption is
likely not useful for the management of most patients
switching to no treatment or to the disease-modifying
therapies employed in this study. The extent and time
course of disease recurrence described in this randomi-
zed prospective study are highly relevant for all patients
discontinuing natalizumab treatment for any reason
and—together with the recognition of risk factors for
PML3—may also inform decisions about the timing
and choice of alternative therapies.
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